Lazard Asset Management LLC Has $3.96 Million Holdings in Avanos Medical, Inc. $AVNS

Lazard Asset Management LLC boosted its position in shares of Avanos Medical, Inc. (NYSE:AVNS) by 12.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 282,642 shares of the company’s stock after purchasing an additional 30,954 shares during the period. Lazard Asset Management LLC owned about 0.60% of Avanos Medical worth $3,960,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of AVNS. Federated Hermes Inc. boosted its position in shares of Avanos Medical by 2.8% during the fourth quarter. Federated Hermes Inc. now owns 25,774 shares of the company’s stock worth $289,000 after buying an additional 691 shares during the period. PNC Financial Services Group Inc. grew its holdings in shares of Avanos Medical by 15.5% during the first quarter. PNC Financial Services Group Inc. now owns 6,317 shares of the company’s stock worth $89,000 after buying an additional 846 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Avanos Medical by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock valued at $386,000 after buying an additional 1,121 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Avanos Medical by 132.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock valued at $28,000 after buying an additional 1,423 shares during the last quarter. Finally, Swiss National Bank raised its position in Avanos Medical by 2.1% in the 4th quarter. Swiss National Bank now owns 91,500 shares of the company’s stock valued at $1,028,000 after buying an additional 1,900 shares during the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Wall Street Analyst Weigh In

AVNS has been the subject of a number of recent research reports. Wall Street Zen downgraded Avanos Medical from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Zacks Research upgraded shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Friday, June 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce”.

Avanos Medical Price Performance

Shares of NYSE AVNS opened at $24.99 on Friday. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -15.52 and a beta of 1.57. The business has a 50-day moving average of $24.94 and a 200-day moving average of $19.71. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.40. Avanos Medical, Inc. has a fifty-two week low of $9.30 and a fifty-two week high of $25.49.

Avanos Medical (NYSE:AVNS) last released its earnings results on Tuesday, May 5th. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.06. The business had revenue of $182.20 million for the quarter, compared to analyst estimates of $170.00 million. Avanos Medical had a positive return on equity of 5.39% and a negative net margin of 10.39%.Avanos Medical’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.26 earnings per share. As a group, sell-side analysts predict that Avanos Medical, Inc. will post 1.06 earnings per share for the current fiscal year.

Avanos Medical Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.